株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

副腎皮質がん:パイプライン製品の分析

Adrenocortical Carcinoma - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 213047
出版日 ページ情報 英文 63 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.53円で換算しております。
Back to Top
副腎皮質がん:パイプライン製品の分析 Adrenocortical Carcinoma - Pipeline Review, H1 2017
出版日: 2017年05月16日 ページ情報: 英文 63 Pages
概要

副腎皮質がんは、副腎皮質に腫瘍が増殖して生じる希少疾患です。発病因子は女性、副腎に影響する遺伝疾患、加齢、喫煙などであり、症状には高血糖、高血圧、下肢の筋力低下、胸部および腹部に過剰に脂肪がつく、子供の早い思春期の兆候、顔面および体毛の増加、特に女性は声が低くなる、等があります。

当レポートでは、世界各国での副腎皮質がん治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

目次

イントロダクション

  • 分析範囲

副腎皮質がんの概要

治療薬の開発

  • 副腎皮質がん向けパイプライン製品:概要
  • 企業別の治療薬
  • 企業で開発中の製品

副腎皮質がん:治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子種類別

副腎皮質がん治療薬の開発に従事している企業

  • ArQule Inc
  • EnGeneIC Ltd
  • Exelixis Inc
  • Merck KGaA
  • Millendo Therapeutics Inc
  • Orphagen Pharmaceuticals Inc

副腎皮質がん:治療薬のプロファイル

副腎皮質がん治療薬:開発休止中のプロジェクト

副腎皮質がん治療薬:開発が中止された製品

副腎皮質がん関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9278IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenocortical Carcinoma - Pipeline Review, H1 2017, provides an overview of the Adrenocortical Carcinoma (Oncology) pipeline landscape.

Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. Predisposing factors include female, hereditary disease that affects the adrenal glands, age and smoking. Symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in chest and abdomen, early signs of puberty in children, increased facial and body hair, particularly in females and deepened voice in females.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenocortical Carcinoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adrenocortical Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Discovery stages are 6 and 1 respectively.

Adrenocortical Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Adrenocortical Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Adrenocortical Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Adrenocortical Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Adrenocortical Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview
    • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development
    • ArQule Inc
    • EnGeneIC Ltd
    • Exelixis Inc
    • Merck KGaA
    • Millendo Therapeutics Inc
    • Orphagen Pharmaceuticals Inc
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drug Profiles
    • ARQ-087 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATR-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avelumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize SF-1 for Cushingis Syndrome, Endometriosis and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TargomiRs - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones
    • Featured News & Press Releases
      • Mar 28, 2017: Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing's Syndrome
      • Mar 18, 2016: Millendo Therapeutics Announces Publication of Preclinical Data for ATR-101 and Data Presentations at ENDO 2016
      • Mar 03, 2015: Atterocor Announces Data Presentations at ENDO 2015
      • Dec 11, 2014: Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers
      • Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by ArQule Inc, H1 2017
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by EnGeneIC Ltd, H1 2017
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Exelixis Inc, H1 2017
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck KGaA, H1 2017
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Millendo Therapeutics Inc, H1 2017
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals Inc, H1 2017
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, H1 2017
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top